Cargando…

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

INTRODUCTION: Number needed to treat (NNT) estimates are a practical metric to help identify the most effective therapies. Our objective is to compare 11 biologic drugs for moderate-to-severe psoriasis in terms of NNT. METHODS: The NNT data were obtained from a Bayesian network meta-analysis of 42 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leonardi, Craig L., See, Kyoungah, Burge, Russel, Sun, Zhuoer, Zhang, Ying, Mallbris, Lotus, Garrelts, Alyssa, Warren, Richard B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9056462/ https://www.ncbi.nlm.nih.gov/pubmed/35316500 http://dx.doi.org/10.1007/s12325-022-02065-w

Ejemplares similares

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort
por: Egeberg, Alexander, et al.
Publicado: (2020)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
por: Warren, Richard B., et al.
Publicado: (2019)

Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis
por: Grace, Elsie, et al.
Publicado: (2019)

Dynamic Visual Representation of Clinical Efficacy of Ixekizumab in Psoriasis
por: Hawkes, Jason E., et al.
Publicado: (2021)

Risk of respiratory infection in patients with plaque psoriasis
por: Svedbom, Axel, et al.
Publicado: (2021)

Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
por: Ravasio, Roberto, et al.
Publicado: (2021)

HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study
por: Mallbris, Lotus, et al.
Publicado: (2009)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
por: Honma, Masaru, et al.
Publicado: (2020)

The Physician Global Assessment and Body Surface Area composite tool is a simple alternative to the Psoriasis Area and Severity Index for assessment of psoriasis: post hoc analysis from PRISTINE and PRESTA
por: Walsh, Jessica A, et al.
Publicado: (2018)

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment
por: Boggs, Robert L, et al.
Publicado: (2014)

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2017)

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
por: Blauvelt, Andrew, et al.
Publicado: (2018)

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey
por: Gorelick, Joe, et al.
Publicado: (2019)

Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(®) Databases
por: Leonardi, Craig, et al.
Publicado: (2022)

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2022)

Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis
por: Armstrong, April, et al.
Publicado: (2022)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
por: Gottlieb, A.B., et al.
Publicado: (2016)

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
por: Geng, Wenjun, et al.
Publicado: (2018)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
por: Blauvelt, Andrew, et al.
Publicado: (2023)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis
por: Blauvelt, A., et al.
Publicado: (2017)

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
por: Leonardi, Craig, et al.
Publicado: (2020)

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
por: Membrive Jiménez, Cristina, et al.
Publicado: (2021)

Study of the Visceral Adipose Tissue in a Cohort of Patients with Moderate-Severe Psoriasis Treated with Biological Therapy
por: Ricardo, Ruiz-Villaverde, et al.
Publicado: (2022)

A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation
por: ZOZAYA, Néboa, et al.
Publicado: (2022)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015)

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
por: Armstrong, April, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hg4n3iqsmngjqkgqklj9batvro